Clinical trials have demonstrated that adult growth hormone deficiency (AGHD) can be effectively treated with Saizen (somatropin, rDNA origin, for injection).
With the US approval, the treatment is now available to patients who were growth hormone deficient during childhood and have growth hormone deficiency as an adult. In addition, adult patients who have adult onset growth hormone deficiency either alone, or associated with multiple hormone deficiencies, now have access to Saizen and its line of devices.
Saizen can be administered using a needle-free device, named Cool Click, the only FDA approved needle-free device for the administration of growth hormone. It can also be administered with a recently launched autoinjector pen device, One Click, or by traditional needle and syringe.